• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effect of verapamil on atherosclerosis.

作者信息

Leonetti G, Sampieri L, Bragato R, Comerio G

机构信息

Ospedale S. Luca, Centro Auxologico Italiano, Milan.

出版信息

Drugs. 1993;46 Suppl 2:75-81. doi: 10.2165/00003495-199300462-00014.

DOI:10.2165/00003495-199300462-00014
PMID:7512486
Abstract

Whether antihypertensive agents exert an antiatherosclerotic effect by blood pressure reduction or independently of their antihypertensive effect is clinically relevant. Animal studies have generally shown that the calcium antagonist verapamil has a preventive rather than a therapeutic antiatherosclerotic effect, which is independent of its antihypertensive effect. However, doses used in animal studies were much higher than those administered to humans and, in animals, the time of administration of verapamil coincided with the application of atherogenic stimulus. Human studies have given controversial results. Verapamil appears to effectively reduce the restenosis rate after coronary angioplasty. However, in patients with coronary stenosis who were undergoing bypass surgery, results were conflicting: a retrospective study provided positive results, while a prospective study gave negative results. An ongoing study investigating the effect of verapamil on the carotid arteries of hypertensive patients could help clarify the relationship between blood pressure reduction and the progression, regression or development of carotid lesions.

摘要

相似文献

1
Effect of verapamil on atherosclerosis.
Drugs. 1993;46 Suppl 2:75-81. doi: 10.2165/00003495-199300462-00014.
2
Atherosclerosis and calcium antagonists: the VHAS. The Verapamil-Hypertension Atherosclerosis Study (VHAS) Investigators.动脉粥样硬化与钙拮抗剂:维拉帕米高血压动脉粥样硬化研究(VHAS)。维拉帕米高血压动脉粥样硬化研究(VHAS)研究者
J Hum Hypertens. 1992 Dec;6 Suppl 2:S45-8.
3
Preliminary clinical experience with calcium antagonists in atherosclerosis. Verapamil in Hypertension Atherosclerosis Study Investigators.钙拮抗剂在动脉粥样硬化中的初步临床经验。维拉帕米高血压动脉粥样硬化研究组。
Drugs. 1992;44 Suppl 1:128-33. doi: 10.2165/00003495-199200441-00024.
4
Preclinical considerations and results with the combination of verapamil and trandolapril: blood pressure reduction and beyond.维拉帕米与群多普利联合应用的临床前考量及结果:血压降低及其他方面
J Hypertens Suppl. 1997 Mar;15(2):S27-33.
5
Antihypertensive treatment and regression of atherosclerosis.抗高血压治疗与动脉粥样硬化的消退
Rev Port Cardiol. 1992 Jul-Aug;11(7-8):623-30.
6
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.钙拮抗剂与非钙拮抗剂治疗冠心病患者高血压的策略。国际维拉帕米-群多普利研究(INVEST):一项随机对照试验。
JAMA. 2003 Dec 3;290(21):2805-16. doi: 10.1001/jama.290.21.2805.
7
Can the coronary atherosclerotic process be influenced by calcium antagonists?
Drugs. 1992;44 Suppl 1:123-7. doi: 10.2165/00003495-199200441-00023.
8
Retardation of development and progression of coronary atherosclerosis: a new indication for calcium antagonists?延缓冠状动脉粥样硬化的发展和进程:钙拮抗剂的新适应证?
Eur J Clin Pharmacol. 1990;39 Suppl 1:S17-23.
9
The antihypertensive effect of verapamil in patients with chronic renal failure.维拉帕米对慢性肾衰竭患者的降压作用。
J Hum Hypertens. 1992 Dec;6 Suppl 2:S41-3.
10
Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.维拉帕米。对其药效学和药代动力学特性以及在高血压治疗中的应用的最新综述。
Drugs. 1989 Jul;38(1):19-76. doi: 10.2165/00003495-198938010-00003.

本文引用的文献

1
Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbit.维拉帕米对高胆固醇喂养家兔动脉粥样硬化的保护机制。
Am J Cardiol. 1984 Oct 1;54(7):884-9. doi: 10.1016/s0002-9149(84)80226-x.
2
Aspirin as an antithrombotic medication.阿司匹林作为一种抗血栓药物。
N Engl J Med. 1983 Dec 15;309(24):1515-7. doi: 10.1056/NEJM198312153092410.
3
Verapamil suppresses atherosclerosis in cholesterol-fed rabbits.
J Am Coll Cardiol. 1983 Jun;1(6):1453-60. doi: 10.1016/s0735-1097(83)80049-7.
4
Failure of a slow channel calcium antagonist, verapamil, to retard atherosclerosis in the Watanabe heritable hyperlipidemic rabbit: an animal model of familial hypercholesterolemia.慢通道钙拮抗剂维拉帕米未能延缓渡边遗传性高脂血症兔的动脉粥样硬化进程:家族性高胆固醇血症的动物模型
J Am Coll Cardiol. 1985 Jul;6(1):141-4. doi: 10.1016/s0735-1097(85)80265-5.
5
Effect of verapamil on accumulation of free and esterified cholesterol in the thoracic aorta of cholesterol-fed rabbits.维拉帕米对喂食胆固醇的家兔胸主动脉中游离胆固醇和酯化胆固醇蓄积的影响。
Atherosclerosis. 1986 Jul;61(1):15-23. doi: 10.1016/0021-9150(86)90109-7.
6
Antiatherogenic activity of FR34235 (Nilvadipine), a new potent calcium antagonist. Effect on cuff-induced intimal thickening of rabbit carotid artery.新型强效钙拮抗剂FR34235(尼伐地平)的抗动脉粥样硬化活性。对兔颈动脉袖套诱导内膜增厚的影响。
Atherosclerosis. 1987 Apr;64(2-3):255-61. doi: 10.1016/0021-9150(87)90253-x.
7
Calcium antagonism and protection of tissues from calcium damage.钙拮抗作用与组织免受钙损伤的保护作用。
J Hypertens Suppl. 1987 Dec;5(4):S37-42. doi: 10.1097/00004872-198712004-00007.
8
Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty.地尔硫卓未能预防经皮腔内冠状动脉成形术后再狭窄。
Am Heart J. 1985 May;109(5 Pt 1):926-31. doi: 10.1016/0002-8703(85)90231-5.
9
Verapamil and diet halt progression of atherosclerosis in cholesterol fed rabbits.维拉帕米和饮食可阻止喂胆固醇家兔的动脉粥样硬化进展。
Cardiovasc Drugs Ther. 1987;1(1):65-9. doi: 10.1007/BF02125835.
10
Effects of calcium antagonists on atherogenesis.钙拮抗剂对动脉粥样硬化形成的影响。
Clin Exp Hypertens A. 1989;11(5-6):1085-96. doi: 10.3109/10641968909035393.